Jonathan Zalevsky Sells 180 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock

Market Beat
2026.02.21 01:17
portai
I'm PortAI, I can summarize articles.

Jonathan Zalevsky, an insider at Nektar Therapeutics (NASDAQ:NKTR), sold 180 shares at an average price of $73.00, totaling $13,140. Following this transaction, he owns 21,174 shares valued at $1,545,702, marking a 0.84% decrease in his position. The sale was disclosed to the SEC. Nektar's stock recently traded down 0.2% to $73.73, with a market cap of $1.50 billion. Analysts have mixed sentiments, with some raising price targets while others cut near-term estimates, leading to a consensus rating of "Moderate Buy" with a target of $119.86.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) insider Jonathan Zalevsky sold 180 shares of the company's stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $73.00, for a total value of $13,140.00. Following the transaction, the insider directly owned 21,174 shares of the company's stock, valued at $1,545,702. This trade represents a 0.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Get Nektar Therapeutics alerts:

  • 3 Bullish Biotech Stocks With Explosive Growth Trends

Jonathan Zalevsky also recently made the following trade(s):

  • On Tuesday, January 20th, Jonathan Zalevsky sold 3,867 shares of Nektar Therapeutics stock. The shares were sold at an average price of $35.67, for a total value of $137,935.89.
  • On Tuesday, November 25th, Jonathan Zalevsky sold 1,157 shares of Nektar Therapeutics stock. The stock was sold at an average price of $54.28, for a total value of $62,801.96.

Nektar Therapeutics Stock Down 0.2%

NASDAQ NKTR traded down $0.13 during trading hours on Friday, hitting $73.73. The company had a trading volume of 997,867 shares, compared to its average volume of 1,224,227. The firm has a market cap of $1.50 billion, a P/E ratio of -9.25 and a beta of 1.34. Nektar Therapeutics has a fifty-two week low of $6.45 and a fifty-two week high of $74.89. The business has a fifty day simple moving average of $45.43 and a 200-day simple moving average of $48.01.

Nektar Therapeutics News Summary

  • Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains

Here are the key news stories impacting Nektar Therapeutics this week:

  • Positive Sentiment: Zacks Research raised multiple multi‑quarter and full‑year EPS projections (FY2026 and FY2027 were revised to smaller losses), indicating improved analyst expectations for Nektar’s future results — a generally constructive signal for the stock. MarketBeat NKTR
  • Positive Sentiment: Nektar announced research collaboration with UCSF to test a TNFR2‑agonist/antibody approach in multiple sclerosis — a meaningful pipeline development that could add long‑term value if clinical data are positive. MSNewsToday: UCSF, Nektar team BioWorld: TNFR2 agonism in MS
  • Neutral Sentiment: An AAII piece compared Nektar to another biotech (Harmony Biosciences) as an investment choice — useful context for longer‑term investors but unlikely to move the stock materially on its own. AAII comparison article
  • Negative Sentiment: Zacks cut near‑term quarter estimates for Q2 2026 (and separately trimmed Q2 2027), signaling some expected near‑term pressure to results that can weigh on sentiment. MarketBeat NKTR

Wall Street Analysts Forecast Growth

NKTR has been the subject of several recent analyst reports. Piper Sandler restated an "overweight" rating and issued a $105.00 target price on shares of Nektar Therapeutics in a research report on Monday, January 26th. William Blair upgraded Nektar Therapeutics from a "market perform" rating to an "outperform" rating in a research report on Tuesday, February 10th. BTIG Research raised their target price on Nektar Therapeutics from $118.00 to $151.00 and gave the company a "buy" rating in a research report on Tuesday, February 10th. Wall Street Zen lowered Nektar Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, November 16th. Finally, HC Wainwright increased their price target on Nektar Therapeutics from $135.00 to $165.00 and gave the stock a "buy" rating in a research note on Tuesday, February 10th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Nektar Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $119.86.

  • Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?

View Our Latest Research Report on Nektar Therapeutics

Institutional Investors Weigh In On Nektar Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of NKTR. Emerald Mutual Fund Advisers Trust bought a new stake in Nektar Therapeutics during the third quarter worth approximately $13,269,000. Simplify Asset Management Inc. boosted its position in shares of Nektar Therapeutics by 67.6% in the 3rd quarter. Simplify Asset Management Inc. now owns 87,174 shares of the biopharmaceutical company's stock valued at $4,960,000 after purchasing an additional 35,176 shares during the period. Emerald Advisers LLC acquired a new position in shares of Nektar Therapeutics in the 3rd quarter valued at $18,393,000. Moody Aldrich Partners LLC increased its stake in Nektar Therapeutics by 62.3% in the 3rd quarter. Moody Aldrich Partners LLC now owns 73,716 shares of the biopharmaceutical company's stock worth $4,194,000 after purchasing an additional 28,304 shares in the last quarter. Finally, Stonepine Capital Management LLC acquired a new stake in Nektar Therapeutics during the 2nd quarter worth about $1,297,000. 75.88% of the stock is owned by institutional investors and hedge funds.

About Nektar Therapeutics

(Get Free Report)

Nektar Therapeutics NASDAQ: NKTR is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body's immune system to treat cancer and other serious diseases.

Nektar's product portfolio and pipeline include a range of clinical-stage and partnered programs.

Featured Articles

  • Five stocks we like better than Nektar Therapeutics
  • Free: The Crypto Summit That Could Change Your Life
  • From Quiet Compounder to 2026 Breakout? BSEM
  • Silver $309?
  • Gilder: Don’t Buy AI Stocks, Do This Instead
  • America’s 1776 happening again

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Nektar Therapeutics Right Now?

Before you consider Nektar Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nektar Therapeutics wasn't on the list.

While Nektar Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Source: Market Beat The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.